Beam Therapeutics base-editing sickle cell therapy succeeds in pivotal trial
Beam Therapeutics announced its base-edited sickle cell therapy met its primary endpoint in a Phase 1/2 clinical trial, potentially positioning it as a third one-time curative therapy for the disease.
